HepQuant to Present at 10th Annual Biotech Showcase Senior Executives Will Also Attend the J.P. Morgan Healthcare Conference DENVER (December 13th, 2017) — HepQuant, LLC, a Greenwood Village, Colo.-based company... read more →
HepQuant Presents at the 2017 Rocky Mountain Life Science Investor and Partnering Conference DENVER (October 12th, 2017) — HepQuant, LLC, a Greenwood Village, Colo.-based company with a unique, patented and... read more →
HepQuant to Hold 2017 Scientific Advisory Board October 21st in Washington, DC DENVER (August 31, 2017) — HepQuant, LLC, a diagnostics company, located in Greenwood Village, CO with unique, patented and... read more →
HepQuant to Sponsor its First Clinical Study Utilizing 3 Investigational Device Exemptions (IDEs) in Clinical Study of Patients with Alcoholic Hepatitis, NASH F3, NASH F4 DENVER (Sep. 28, 2017) —... read more →
HepQuant Announces Approval of Fourth Investigational Device Exemption Application HepQuant SHUNT™ Liver Diagnostic Kit for use in a clinical study in subjects with Alcoholic Hepatitis DENVER (September 14, 2017) — HepQuant,... read more →
HepQuant Completes Third State-Sponsored Grant State of Colorado funding enables advancement of supply chain, regulatory advancements and HepQuant laboratory DENVER (August 31, 2017) — HepQuant, LLC, a diagnostics company, located... read more →
HepQuant Test Inventor and Founder Doctor Gregory T. Everson Accepts Position of CEO DENVER (July 1, 2017) — HepQuant, LLC, a Greenwood Village, Colo.-based company with a unique, patented and patent-pending... read more →